Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

(NASDAQ:PALI), Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands Capital, Deep Track Capital, Janus Henderson Investors, Octagon Capital, Perceptive Advisors, RA Capital Management, Squadron Capital Management, and a large healthcare dedicated mutual fund Proceeds to support upcoming […]

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

(NASDAQ:DYN), WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to

TEN Ltd. Declares Dividend on its Series F Cumulative Redeemable Perpetual Preferred Shares

(NYSE:TEN),(NYSE:TEN-PF), ATHENS, Greece, Oct. 02, 2025 (GLOBE NEWSWIRE) — TEN Ltd. (“TEN”) (NYSE: TEN) (the “Company”), a leading diversified crude, product and LNG tanker operator, today announced that its Board of Directors declared the regular quarterly cash dividend of approximately $0.59375 per share for its Series F Cumulative Redeemable Perpetual Preferred Shares (the “Series F

Rumble and Perplexity Enter into a Strategic Partnership

(NasdaqGM:RUM), Collaboration to drive improved video discovery on Rumble by leveraging Perplexity AI tools Rumble will introduce a new bundled subscription offer combining Perplexity Pro with Rumble Premium Partnership includes an advertising commitment from Perplexity to promote its new AI-based browser Comet to the Rumble audience LONGBOAT KEY, Fla., Oct. 02, 2025 (GLOBE NEWSWIRE) —

CCSC Technology International Holdings Limited Announces Closing of a $7.06 Million Public Offering

(NASDAQ:CCTG), HONG KONG, Oct. 02, 2025 (GLOBE NEWSWIRE) — CCSC Technology International Holdings Limited (the “Company”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced the closing of its previously announced best-efforts public offering (the “Offering”) of (i) 11,766,627

Rush Enterprises, Inc. Conference Call Advisory for Third Quarter 2025 Earnings Results

(NASDAQ:RUSHA),(NASDAQ:RUSHB), NEW BRAUNFELS, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) — Rush Enterprises, Inc., (NASDAQ: RUSHA & RUSHB), which operates the largest network of commercial vehicle dealerships in North America, will host a conference call to discuss earnings for the third quarter of 2025 on Thursday, October 30 at 10:00 a.m. Eastern/9:00 a.m. Central. Earnings will

Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

(NASDAQ:VERO), TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 545,335

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

(NASDAQ:TNYA), SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the following October investor

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

(NASDAQ:TERN), FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

(NASDAQ:CRDF), SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025. Details of the events can be found below. Piper Sandler

Scroll to Top